Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shyndec Pharma Pays $49 Million for 30% of Rongsheng Pharma

publication date: Feb 28, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Shyndec Pharmaceutical will acquire the 30% stake in Sinopharm Rongsheng Pharma it doesn’t already own for $48.8 million. Before the transaction, Rongsheng was already contributing almost half of Shyndec’s profits. The closing of the transaction will raise Shyndec’s profits by 20%. Both companies are part of China’s state-owned pharmaceutical giant Sinopharm. More details....

Stock Symbol: (SH: 600420)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...